Navigation Links
/R E P E A T -- Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours/
Date:9/2/2008

gene amplification in their tumours (metastatic or primary) in order to qualify for the trial.

The primary objectives of the Phase 2 trial are to determine the objective response rate of REOLYSIN(R) in combination with paclitaxel and carboplatin in patients with metastatic or recurrent NSCLC with K-RAS or EGFR-activated tumours, and to measure progression-free survival at 6 months. The secondary objectives are to determine the median survival and duration of progression-free survival in patients, and to evaluate the safety and tolerability of REOLYSIN(R) in combination with paclitaxel and carboplatin in this patient population.

REOLYSIN(R) preferentially replicates in cancer cells that have an activated RAS pathway. Approximately two thirds of all cancers have an activated RAS pathway, including most metastatic disease. A large number of mutations, including mutations in EGFR, Her2 or K-RAS along the RAS pathway lead to RAS pathway activation.

Recent clinical studies in NSCLC with EGFR-based therapies have shown that patients with mutations or overexpression of EGFR, which are commonly found in NSCLC, derive clinical benefit from these therapies. An agent such as REOLYSIN(R) that selectively replicates in cancers with an activated RAS pathway resulting from EGFR mutations or overexpression may show similar benefit. However, patients with mutant K-RAS, or up to 20% of the more than 180,000 patients diagnosed every year in the U.S. with NSCLC, do not derive benefit from EGFR-based therapies. The introduction of screening for K-RAS mutations, and the exclusion of K-RAS mutated patients will lead to higher response rates in EGFR-mutated or overexpressed patients treated with EGFR-based therapies. This excluded patient group is therefore prescreened for RAS pathway activation resulting from mutations in K-RAS, and an agent such as REOLYSIN(R) may be indicated for this patient group. This study targets patients with either EGFR-activated tumours or K
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours
2. Oncolytics Biotech Inc. Completes Dose Escalation in Combination REOLYSIN(R)/Docetaxel Trial
3. Oncolytics Biotech Inc. Announces 2008 Second Quarter Results
4. Oncolytics Biotech Inc. Treats 200th Cancer Patient in Clinical Studies with REOLYSIN(R)
5. Oncolytics Biotech Inc. Announces U.S. Phase 2 Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin
6. Oncolytics Biotech Inc. to Present at BIO 2008 International Convention
7. Oncolytics Biotech Inc. Announces Start of Enrolment in Phase 1/2 Ovarian Cancer Clinical Trial with REOLYSIN(R)
8. Oncolytics Biotech Inc. Starts Patient Enrolment in U.K. Phase II Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin
9. Oncolytics Biotech Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at ASCO Annual Meeting
10. Oncolytics Biotech Inc. Collaborators to Present Reovirus Research at ASGT Meeting
11. Oncolytics Biotech Inc. Announces Issuance of 9th Canadian Patent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... With bed bugs' presence come problems in various terms. ... to be eliminated, one must make sure that the bed ... so to help bed bug sufferers get that done, it ... bugs without using harmful pesticides. In it, the company ... Bug Bully. , According to My Cleaning Products, contrary to ...
(Date:5/20/2013)... Interventional cardiologist Tony Farah, MD, and his ... Cardiovascular Institute have helped pioneer many breakthroughs in ... over the past three decades, from new disease-fighting medications ... artery stent implantation. , Today, AGH officials announced that ... in the study of a novel, first-of-its kind investigational ...
(Date:5/20/2013)... Maryland (PRWEB) May 20, 2013 In ... in the field of biotoxin related illnesses , announced ... the country able to advance his protocol for treating ... Patel became the third physician to achieve certification in ... Certified Physicians, able to practice the Shoemaker Protocol in ...
(Date:5/17/2013)... GA (PRWEB) May 17, 2013 Dr. ... Gynecology, and Women’s Health at the Albert Einstein College ... Oncology at the Montefiore Medical Center. He is ... Cancer Center and leads the Einstein Breast Cancer Working ... on translational breast cancer research. He also serves as ...
Breaking Biology Technology:New Non Pesticide Discovery on How to Get Rid of Bed Bugs Tipped by My Cleaning Products 2Allegheny General Hospital Cardiovascular Institute Becomes Exclusive Pittsburgh Site for Study of Novel Coronary Artery Disease Device 2Allegheny General Hospital Cardiovascular Institute Becomes Exclusive Pittsburgh Site for Study of Novel Coronary Artery Disease Device 3Allegheny General Hospital Cardiovascular Institute Becomes Exclusive Pittsburgh Site for Study of Novel Coronary Artery Disease Device 4Dr. Ritchie Shoemaker Certifies Third Physician in His Treatment Protocol for Chronic Inflammatory Response Syndrome (CIRS) 2Joseph A. Sparano, MD, Named Vice Chair of ECOG-ACRIN Cancer Research Group 2Joseph A. Sparano, MD, Named Vice Chair of ECOG-ACRIN Cancer Research Group 3
... DRRX ) announced today that management is scheduled to present ... -- Needham & Company,s Biotechnology and Medical Technology Conference ... EDT. -- Leerink Swann,s Pain Roundtable Conference, on Monday, June ... Jefferies, 2nd Annual Healthcare Conference on Thursday, June 26th at ...
... June 5 BioTrends Research Group, Inc.,released its ... the management of psoriasis. This report is based ... US Dermatologists in April,2008., According to the ... their use of biologics for the treatment of ...
... BSX ) is scheduled to participate in Goldman ... in Dana Point,CA., Jim Tobin, Boston Scientific Chief ... followed by a 25-minute question and,answer session on Wednesday, ... live webcast of Mr. Tobin,s remarks will be available ...
Cached Biology Technology:Dermatologists Report Increased Use of Biologics in the Treatment of Psoriasis 2
(Date:5/16/2013)... A scientist has discovered an ancient extinct creature with ... it in honour of his favourite movie star. ... Kooteninchela deppi (pronounced Koo-ten-ee-che-la depp-eye), which is a ... the actor Johnny Depp for his starring role as ... named Edward, an unfinished creation, who has scissors for ...
(Date:5/16/2013)... outside the bone marrow in the liver, the ... now show that a specific type of immune cell ... Balanced hematopoiesis is essential for the function of the ... in the liver and the spleen. Later the process ... normally serves as the sole source of blood cells ...
(Date:5/16/2013)... the world are meeting next week in Toronto. ... the latest in research findings about the brain, ... the disorders that affect them., "Canada is a ... showcase the best of neuroscience research done here ... of the Canadian Association for Neuroscience. He also ...
Breaking Biology News(10 mins):Actor Johnny Depp immortalized in ancient fossil find 2Herpes infections: Natural killer cells activate hematopoiesis 27th Annual Canadian Neuroscience Meeting, Toronto, May 20-24, 2013 2
... Academy of Sciences will launch the most comprehensive scientific ... terrestrial and marine life forms from the tops of ... They will be joined by colleagues from the University ... National Museum and the Philippines Bureau of Fisheries and ...
... Bethesda, MD FASEB MARC (Minority Access to ... for The Endocrine Society,s 93rd Annual Meeting and Expo ... awards are meant to promote the entry of underrepresented ... the basic science community and to encourage the participation ...
... RUSTON, La. Dr. Yuri Lvov, professor of chemistry ... at Louisiana Tech University, recently led a symposium at ... discussing his application of a more eco-friendly and cost-effective ... properties of plastics, paints and other synthetic composites. ...
Cached Biology News:California Academy of Sciences launches scientific expedition to the Philippines 2California Academy of Sciences launches scientific expedition to the Philippines 3California Academy of Sciences launches scientific expedition to the Philippines 4California Academy of Sciences launches scientific expedition to the Philippines 5Louisiana Tech researcher presents on eco-friendly nanotechnology at national conference 2
... is a tetramethylrhodamine-conjugated jetSI-ENDO (excitation ... 580 nm), the powerful siRNA ... used to determine the transfection ... delivery and trafficking of siRNAs. ...
... TrackerCumulates a score of movement counts, similar ... it.can track up to 6 subjects at once, ... triggered. Test a whole experimental group at ... the activity. Upgradeable for a variety of ...
... OutputCumulates a score of movement counts, similar to ... track up to 6 subjects at once, in ... Can outpt a sync pulse to coordinate ... use animal location and timing information to control ...
... features of Tracker, plus software to note when ... of the arena, and trigger a penaltyThe Spatial ... built around a video camera, frame grabber, and ... fields at once and up to 6 moving ...
Biology Products: